When Akero Therapeutics failed to meet the 36-week primary endpoint in its Phase IIb SYMMETRY study of efruxifermin in metabolic dysfunction-associated steatohepatitis (MASH) in October 2023, the company argued that the study showed a positive numerical direction and that longer-term treatment might demonstrate a statistically significant benefit, a view some analysts seconded because the study enrolled the sickest MASH patients, those with cirrhosis (F4 fibrosis).
Key Takeaways
- Akero’s efruxifermin is the first MASH candidate to show a fibrosis benefit in cirrhotic patients in 96-week data from a Phase IIb study.
In 96-week data from SYMMETRY reported on 27 January, Akero’s 15-month-old assertion proved true, as 39% of patients receiving a...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
